NMNicky J. Mehtani

Nicky J. Mehtani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicky J. Mehtani has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Joanna Eveland

    Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, CA; and

    4 shared publications
  • Mallory O. Johnson

    Department of Medicine, University of California, San Francisco, San Francisco, California, USA

    4 shared publications
  • Sarah Strieff

    Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California, USA

    4 shared publications
  • Alix Strough

    Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California

    3 shared publications
  • Monica Gandhi

    Department of Medicine, University of California, San Francisco, San Francisco, California, USA

    3 shared publications
  • Barry Zevin

    Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California

    2 shared publications

Latest Publications

  • Open Access

    Delivering Long-Acting Injectable Cabotegravir PrEP to People Experiencing Homelessness and People Who Use Drugs

    by Nicky J. Mehtani, Stephen J. Matzat, Anoushka Rustagi, Hannah Stowe, Sarah Strieff, Derek Sportsman, Morgan M. Philbin, Monica Gandhi, Mallory O. Johnson

    Long-acting injectable cabotegravir (CAB-LA) may be particularly advantageous for preventing HIV among people experiencing homelessness (PEH) and people who use drugs (PWUD), populations at high HIV risk with poor oral pre-exposure prophylaxis (PrEP) outcomes. In a retrospective study using the RE-AIM framework to organize programmatic outcomes, we evaluated real-world implementation of CAB-LA at the Maria X. Martinez Health Resource Center, a status-neutral, fully drop-in municipal clinic in San Francisco, CA, serving >4000 patients annually for diverse health needs. We included all patients prescribed CAB-LA between October 2022 and December 2025. Outcomes included reach, adoption, implementation (injection timeliness, delivery setting, guideline-concordant HIV monitoring), maintenance (retention), and exploratory effectiveness (HIV acquisitions relative to active coverage). Nineteen providers prescribed CAB-LA to 68 patients (63% experiencing homelessness; 56% with stimulant use disorder, 34% opioid use disorder, 51% psychotic-spectrum illness); 52 (76%) received ≥1 injection. Of 304 injections, 42% occurred outside the clinic, including in shelters, on the street, and in jail or inpatient settings; 76% of follow-up injections were on time. HIV testing concordant with the Centers for Disease Control and Prevention guidelines (antigen/antibody plus RNA) accompanied 37% of injections. Twelve-month retention was 49%. Two patients acquired HIV, both during gaps in CAB-LA coverage. Sustaining coverage required intensive outreach, population tracking, insurance reenrollment, and financial incentives. Findings suggest that CAB-LA can be delivered in a fully drop-in clinic serving PEH and PWUD, while highlighting the resource-intensive support required to maintain coverage. Adapting delivery models, laboratory monitoring protocols, and financing to the realities of structurally vulnerable populations is essential to extend the benefits of long-acting PrEP.

  • Open Access

    Long-Acting Antiretroviral Therapy for HIV via Drop-in Community-Based Care

    by Nicky J. Mehtani, Stephen J. Matzat, Kathleen B. O’COnnor, Laura Cordoba, Sarah Strieff, Alix Strough, Morgan M. Philbin, Mallory O. Johnson, Monica Gandhi, Barry Zevin

    Importance: People with HIV (PWH) experiencing homelessness face barriers to daily oral antiretroviral therapy (ART) adherence and often lack access to HIV specialty care. Data are needed on the feasibility and outcomes of long-acting ART (LA-ART) delivery within low-barrier, community-based settings. Objective: To evaluate the implementation and effectiveness of LA-ART delivery at a community-based drop-in clinic for people experiencing homelessness (PEH). Design, Setting, and Participants: This quality improvement study included PWH experiencing homelessness or housing instability, among whom substance use and psychiatric disorders were prevalent, receiving care at the Maria X. Martinez Health Resource Center, a municipal clinic serving PEH in San Francisco, California. Programmatic outcomes of LA-ART were evaluated from November 2021 through October 2025, with a secondary descriptive evaluation of PWH receiving standard treatment vs LA-ART between January 2023 and December 2024. Intervention: Intramuscular cabotegravir-rilpivirine injection, with or without lenacapavir, delivered within a high-touch model incorporating reminders, outreach, and flexible delivery compared with standard treatment consisting of oral ART when accepted. Main Outcomes and Measures: Outcomes were viral suppression (HIV RNA <200 copies/mL) and clinical encounters per person-year between 2023 and 2024. Among LA-ART recipients, additional outcomes included retention, injection timeliness, out-of-clinic administration, and virologic failure over the full program period. Results: Among 128 PWH included in the 2023-2024 descriptive cohort, 24 individuals (mean [SD] age, 44.6 [12.2] years; 15 cisgender males [63%]) received LA-ART, and 123 individuals (mean [SD] age, 42.6 [12.1] years; 69 cisgender males [66%]) received standard treatment (due to treatment transitions, treatment conditions were not mutually exclusive). All 24 (100%) individuals receiving LA-ART achieved and maintained viral suppression. Among those receiving standard treatment, 89 of 123 (72%) ever achieved viral suppression and 69 of 123 (56%) had viral suppression at last follow-up. The mean (SD) number of clinical encounters per person-year was higher for LA-ART recipients (23.0 [11.1] vs 9.1 [11.5]). Across the full program period, 30 individuals initiated LA-ART, and all continued receiving therapy through October 2025 (median duration [range], 106 [8-206] weeks). Of 637 injection visits, 43 (7%) were delayed by more than 7 days and 21 (3%) by more than 14 days, and 121 (19%) were administered outside the clinic. Three individuals experienced virologic failure while receiving cabotegravir-rilpivirine and achieved resuppression after the addition of lenacapavir. Conclusions and Relevance: In this quality improvement study, LA-ART delivery within a high-touch, flexible care model in a drop-in clinic serving PEH was associated with high rates of viral suppression. These findings highlight the potential for nonspecialty, community-based settings to deliver LA-ART to structurally vulnerable populations, while underscoring the substantial programmatic support required.


  • Open Access

    Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders

    by Nicky J. Mehtani, Maha N. Mian, Gabrielle Agin-Liebes, Allison R. Coker, Christopher Huebner, Brian T. Anderson, Jennifer M. Mitchell

    Amid an evolving psychedelic drug policy landscape and limitations of existing substance use disorder (SUD) treatments, a novel addiction recovery paradigm has emerged involving augmentation of 12-Step program engagement with therapeutic psychedelic use. A preliminary qualitative analysis was initiated to describe this movement by examining real-world experiences of participants in remission from alcohol, opioid, and stimulant use disorders. Between November 2022 and February 2023, data collection was piloted with nine individuals reporting ayahuasca, ibogaine, psilocybin, and/or peyote use in combination with 12-Step engagement. Participants were intentionally recruited through a community partner to explore this emerging phenomenon; findings are not intended to generalize to broader 12-Step communities. Motivations included challenges with sobriety, psychological distress during abstinence, dissatisfaction with existing SUD treatments, and the relative accessibility of this community-based approach compared to clinical care. Participants highlighted reduced SUD-related cravings, psychospiritual mechanisms of behavior change, and synergistic effects of psychedelics with Steps 2, 4, and 11. Tensions with abstinence-oriented philosophies were acknowledged, and risks related to unsupervised psychedelic use were central to participants' narratives; however, participants ultimately found that psychedelics enhanced their recovery by deepening actionable Step-work and improving psychosocial well-being. Pilot findings underscore a need for further research into this low-cost, accessible approach.


  • Open Access

    Ketamine-Assisted Recovery (KARE): protocol for an open-label pilot trial of ketamine-assisted psychotherapy for publicly insured patients with methamphetamine use disorder and HIV risks

    by Nicky J. Mehtani, Brian T. Anderson, Irina Alexander, Peter S. Hendricks, Jennifer M. Mitchell, Phillip O. Coffin, Mallory O. Johnson

    Introduction Methamphetamine use disorder (MeUD) is a debilitating condition with no FDA-approved pharmacotherapies that has been associated with poor neurological, psychiatric and cardiovascular outcomes, particularly among low-income populations. The use of methamphetamine also increases risks for sexually transmitted infections (STIs) by reducing behavioural inhibitions while enhancing sexual libido, disproportionately affecting sexual and gender minorities. The overlap of MeUD with HIV risks and psychological trauma underscores the need for innovative, accessible and culturally responsive therapies. Ketamine-assisted psychotherapy (KAP), which has shown promise for treatment-resistant depression and other substance use disorders, has yet to be explored for MeUD. The Ketamine-Assisted Recovery (KARE) trial seeks to address this gap. Methods and analysis KARE is an open-label pilot study enrolling N=12–24 Medicaid-insured or Medicare-insured adults with moderate-to-severe MeUD and HIV risk factors. Participants will undergo three office-based intramuscular ketamine (0.50–0.75 mg/kg) sessions in combination with seven sessions of motivational enhancement therapy over 5 weeks. Recruitment efforts target community-based organisations, outpatient clinics offering HIV and STI testing/treatment, and substance use disorder treatment programmes. Feasibility, acceptability and tolerability will be assessed via recruitment and a priori retention benchmarks, surveys and semistructured interviews exploring participants’ perceptions of KAP and ketamine’s misuse potential. Safety will be evaluated through systematic monitoring for adverse events and serial measurement of vital signs during dosing. , craving, withdrawal, HIV risk behaviours and psychological distress, as well as psychological and cognitive flexibility as potential mechanisms of ketamine’s effects, laying the groundwork for future randomised controlled trials. Ethics and dissemination Ethics approval has been obtained from the University of California, San Francisco Institutional Review Board (24-41588) and the Research Advisory Panel of California (202422S). Results will be disseminated through national conferences, peer-reviewed publications and presentations to community-based stakeholders. Trial registration number NCT06538285.


  • Open Access

    HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series

    by Nicky J Mehtani, Janet Grochowski, Anthonia Chimezie, Alix Strough, Sarah Strieff, Monica Gandhi

    Lenacapavir, a long-acting human immunodeficiency virus (HIV) capsid inhibitor, is thought to have a low resistance barrier based on current, limited data. We describe 4 patients experiencing homelessness with severe mental illness who maintained HIV suppression (<30 copies/mL) despite unintentional receipt of lenacapavir monotherapy for 9–38 weeks, highlighting its potential among adherence-challenged populations.


  • A systematic review of income and education reporting in psychedelic clinical trials

    by Daniel H. Grossman, Kevin R. Madden, Nicky J. Mehtani, Brian T. Anderson, Lori L. Davis, Jennifer M. Mitchell, Peter S. Hendricks

    Socioeconomic status (SES) substantially influences mental health outcomes and treatment access, yet its reporting in psychedelic-assisted therapy trials remains underexplored. Here we systematically reviewed 98 articles (49 primary trials and 49 secondary analyses) published between 2006 and 2024 examining classic psychedelics and MDMA for mental health conditions. Only 12% of primary trials reported participant income data, and 31% reported educational attainment. In US-based trials, participants showed markedly higher SES than the general population: 93% had some college education (versus 62% nationally), and median incomes in major trials substantially exceeded the national median for all workers. Non-US trials showed variable patterns. This widespread underreporting of SES data and evidence of socioeconomic disparities, particularly in US trials, highlights an urgent need for standardized SES reporting and targeted strategies to improve socioeconomic diversity in psychedelic-assisted therapy research, ensuring broader generalizability and access to these emerging treatments.


  • Open Access

    Psilocybin-assisted therapy and HIV-related shame

    by Nicky J. Mehtani, Mallory O. Johnson, Peter S. Hendricks, Jennifer Mitchell, Brian T. Anderson

    As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic, in part due to limited success of conventional psychotherapies in addressing HIV-related shame. In a pilot clinical trial (N = 12), receipt of psilocybin-assisted group therapy was associated with a large pre-post decrease in HIV-related shame as measured by the HIV and Abuse Related Shame Inventory, with a median (IQR) change of − 5.5 (− 6.5, − 3.5) points from baseline to 3-months follow-up (Z = − 2.6, p = 0.009, r = − 0.75). A paradoxical exacerbation of sexual abuse-related shame experienced by two participants following receipt of psilocybin raises critical questions regarding the use of psilocybin therapy among patients with trauma. These preliminary findings carry potential significance for the future of HIV care.


  • Top Cited Papers

    Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment and Prevention for People Experiencing Homelessness

    by Nicky J. Mehtani, Alix Strough, Sarah Strieff, Barry Zevin, Joanna Eveland, Elise D. Riley, Monica Gandhi

    Background: Long-acting (LA) antiretrovirals may provide meaningful benefit to people who use drugs and people experiencing homelessness (PEH) who face disproportionate structural and psychosocial barriers in adhering to daily oral HIV antiretroviral therapy or pre-exposure prophylaxis (PrEP), but their use in these populations has not been studied. Setting: The Maria X. Martinez Health Resource Center is a low-barrier (eg, no appointment) community-based clinic serving San Francisco PEH. Methods: A multidisciplinary care model with robust monitoring and outreach support was developed to provide LA antiretroviral therapy (ART) and LA-PrEP to eligible patients experiencing difficulties adhering to oral antiretrovirals. Feasibility was assessed by evaluating the rates of HIV viremia and on-time injections among patients receiving LA antiretrovirals over the first 24 months of program implementation. Results: Between November 2021 and November 2023, 33 patients initiated LA-ART or LA-PrEP (median age, 37 years; 27% transgender/nonbinary; 73% non-White; 27% street homeless; 52% sheltered homeless; 30% with opioid use disorder; 82% with methamphetamine use disorder). Among 18 patients with HIV, 14 initiated LA-ART injections with detectable viremia (median CD4 count, 340 cells/mm3; mean log10 viral load, 3.53; SD, 1.62), 8 had never previously been virally suppressed, and all but 1 achieved or maintained virologic suppression (mean, 9.67 months; SD, 8.30). Among 15 LA-PrEP patients, all remained HIV negative (mean, 4.73 months; SD, 2.89). Of 224 total injections administered, 8% were delayed >7 days. Discussion: The implementation of LA antiretrovirals is feasible in low-barrier, highly supportive clinical settings serving vulnerable PEH. Expansion of such programs will be critical in ending the HIV epidemic.


  • Open Access

    Housing Instability Associated with Return to Stimulant Use among Previously Abstaining Women

    by Nicky J. Mehtani, Chika C. Chuku, Meredith C. Meacham, Eric Vittinghoff, Samantha E. Dilworth, Elise D. Riley

    Stimulant use among unstably housed individuals is associated with increased risks of psychiatric co-morbidity, violence, HIV transmission, and overdose. Due to a lack of highly effective treatments, evidence-based policies targeting the prevention of stimulant use disorder are of critical importance. However, little empirical evidence exists on risks associated with initiating or returning to stimulant use among at-risk populations. In a longitudinal cohort of unstably housed women in San Francisco (2016–2019), self-reported data on stimulant use, housing status, and mental health were collected monthly for up to 6 months, and factors associated with initiating stimulants after a period of non-use were identified through logistic regression. Among 245 participants, 42 (17.1%) started using cocaine and 46 (18.8%) started using methamphetamine. In analyses adjusting for demographics and socio-structural exposures over the preceding month, experiencing street homelessness was associated with initiating cocaine use (AOR: 2.10; 95% CI: 1.04, 4.25) and sheltered homelessness with initiating methamphetamine use (AOR: 2.57; 95% CI: 1.37, 4.79). Other factors—including race, income, unmet subsistence needs, mental health, and treatment adherence—did not reach levels of significance, suggesting the paramount importance of policies directed toward improving access to permanent supportive housing to prevent stimulant use among unstably housed women.


  • Perceptions on Navigating ACGME-Accredited Addiction Psychiatry Fellowship Program Websites: A Thematic Analysis across a Race- and Gender-Diverse Pool of Potential Applicants

    by Matthew P. Abrams, Danielle S. Jackson, Amaka Aneke-Gratia, Anne E. Kohler, Nicky Mehtani, Ayana Jordan

    Background: There is an alarming shortage of addiction psychiatrists in the United States. To promote interest in addiction psychiatry (ADP), it is essential to maximize resources available through ADP fellowship websites. The aim of this study was to investigate the perceived adequacy and accessibility of content on ADP fellowship websites and discover what further information is considered important among trainees interested in becoming addiction specialists. Methods: Three virtual focus groups were conducted between January and February 2021 among medical students and residents in diverse geographic regions. Participants were asked about the availability of information on ADP fellowship program websites and other material they would like to see available. Focus groups were recorded, with data transcribed and coded using NVivo 11 and Dedoose. A coding scheme was deductively developed based on the core research questions. Results: The majority of participants (N = 27) identified areas of dissatisfaction with the content currently available on ADP websites. The sample was highly representative of racial and ethnic minoritized trainees (n = 12) and genderqueer/non-binary participants (n = 3). Three major themes were identified and durable across all focus groups: lack of emphasis on diversity/health equity, lack of portrayal of everyday life and activities of fellows, and inadequate representation of curricula. Overwhelmingly, participants identified a dedication to health equity (for example, working with minoritized populations) as a key deciding factor in whether to apply to a particular ADP fellowship. Conclusions: ADP fellowship websites are perceived to have considerable variability in the amount and quality of information. Many do not appear to provide the full spectrum of content desired by diverse potential applicants, such as information regarding current fellows and community-centered initiatives. This is concerning, as it suggests ADP fellowships may be interfacing poorly with burgeoning leaders, especially those from race and gender minoritized backgrounds, neglecting potential opportunities to develop future addiction specialists.